Conformis Inc: management transactions · United States · SEC (Form 4)

About Conformis Inc

Conformis Inc. (ticker: CFMS) is a U.S. medical technology company listed on NASDAQ in the United States. Founded in 2004, the company built its identity around a proprietary patient-specific orthopedics model centered on its iFit Image-to-Implant platform, which uses imaging data to design, manufacture, and commercialize implants tailored to each patient’s anatomy. Its operations have historically been based in the Boston, Massachusetts area, including facilities in Billerica, and the company has developed integrated capabilities across design, manufacturing, and commercialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1305773/000130577318000016/cfms-123117x10k.htm?utm_source=openai)) Conformis’ core business is personalized joint replacement, with a primary focus on the knee and a secondary presence in hip arthroplasty. Its product history includes the iUni, iDuo, iTotal CR, iTotal PS, and the Conformis Hip System. The company’s proposition is to provide individually sized implants and associated surgical instrumentation intended to improve anatomic fit, operating-room workflow, and potentially clinical outcomes. In competitive terms, Conformis operates in a market dominated by large global orthopedics players, so its positioning is that of a differentiated specialty medtech company rather than a scale leader. Its competitive edge has historically depended more on product innovation, intellectual property, and surgeon adoption than on broad manufacturing scale. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1305773/000130577318000016/cfms-123117x10k.htm?utm_source=openai)) The company was incorporated in 2004 and moved into commercial operations during the following years, introducing its first products in 2007 and later rolling out successive generations of knee systems before adding hip. SEC filings also show that Conformis financed growth through multiple private rounds before its IPO in July 2015. That history is important for investors because it reflects a medtech business with meaningful R&D intensity and a long development-to-commercialization cycle, often requiring outside capital to support growth, manufacturing scale-up, and market expansion. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1305773/000130577318000016/cfms-123117x10k.htm?utm_source=openai)) Geographically, Conformis has pursued commercial reach beyond the U.S., including a European presence, while maintaining its main operational base in the United States. The company has also emphasized its patent portfolio and proprietary know-how as strategic assets. In terms of recent context, the publicly available sources reviewed confirm ongoing SEC reporting activity and insider-transaction filings around CFMS, which is consistent with a listed issuer subject to regular disclosure. For French-speaking investors, Conformis should be viewed as a niche small-cap medtech name with technology-driven differentiation, but also with execution risk tied to clinical adoption, reimbursement dynamics, and competition from much larger orthopedic groups. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1305773/000130577323000013/cfms-20221231.htm?utm_source=openai))